Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

January 24, 2017

Study Completion Date

January 24, 2017

Conditions
Asthma
Interventions
DRUG

Benralizumab

Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

DRUG

Benralizumab Placebo

Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

DRUG

Seasonal influenza virus vaccine

Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

Trial Locations (24)

29420

Research Site, North Charleston

33135

Research Site, Miami

33173

Research Site, Miami

33180

Research Site, Aventura

35209

Research Site, Birmingham

55402

Research Site, Minneapolis

68123

Research Site, Bellevue

73034

Research Site, Edmond

73103

Research Site, Oklahoma City

76018

Research Site, Arlington

76712

Research Site, Waco

78130

Research Site, New Braunfels

78221

Research Site, San Antonio

78251

Research Site, San Antonio

79903

Research Site, El Paso

80230

Research Site, Denver

80907

Research Site, Colorado Springs

84015

Research Site, Clinton

85206

Research Site, Mesa

92647

Research Site, Huntington Beach

92663

Research Site, Newport Beach

97504

Research Site, Medford

80012-4016

Research Site, Aurora

08225

Research Site, Northfield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY